{"id":"W4380078977","doi":"10.1002/hon.3164_442","title":"First interim analysis of a phase 1 study of zanubrutinib (zanu) + lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"AbbVie Canada; BeiGene; Regeneron Pharmaceuticals","keywords":"Medicine; Lenalidomide; Internal medicine; Refractory (planetary science); Interim analysis; Diffuse large B-cell lymphoma; Oncology; Lymphoma; Gastroenterology; Clinical trial; Multiple myeloma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006767206,0.002178335,0.002533685,0.0006037232,0.00080945,0.001282841,0.001029748,0.001217129,0.00524833],"category_scores_gemma":[0.002929741,0.0006627676,0.003006662,0.0005369505,0.0007921623,0.001181701,0.0007745015,0.002878415,0.001050163],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001133593,"about_ca_system_score_gemma":0.002679796,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003706291,"about_ca_topic_score_gemma":0.0009569922,"domain_scores_codex":[0.9981,0.0008577053,0.0001332801,0.0002877241,0.0002124203,0.0004090004],"domain_scores_gemma":[0.9980499,0.0003286735,0.0005268142,0.000357827,0.0002225193,0.0005142904],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8597001,0.02583018,0.01878728,0.0008749734,0.005177756,0.0003433412,0.0002148554,0.004128809,0.01536837,0.000554107,0.01152604,0.05749423],"study_design_scores_gemma":[0.3864939,0.5209718,0.05460198,0.00008927829,0.005945969,0.0004920626,0.0001029758,0.00468322,0.01014244,0.001457441,0.01491544,0.0001035223],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9375355,0.003132173,0.006171436,0.001195554,0.0006600784,0.02556496,0.01634529,0.0005555807,0.008839465],"genre_scores_gemma":[0.9420981,0.001008469,0.008229099,0.001956312,0.0002720653,0.02185418,0.01924023,0.0001345554,0.005206835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006767206,"threshold_uncertainty_score":0.03578889,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03837858987535493,"score_gpt":0.3586103973826119,"score_spread":0.3202318075072569,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}